BFM
IRLA

Boothbay Fund Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Boothbay Fund Management’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Buy
+13,911
New +$320K ﹤0.01% 1818
2020
Q4 		– Sell
-23
Closed -$204K – 1384
2020
Q3 		$230K Buy
+23
New +$209K 0.01% 906

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boothbay Fund Management's IRLA Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026: 13,911 shares worth $253K. The stake represents ﹤0.01% of the portfolio and ranks #1818 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in IRLA as recently as Q3 2020.

Boothbay Fund Management first reported a position in IRLA in Q3 2020 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • Boothbay Fund Management held 13,911 shares of IRulya Therapeutics Inc. Common Stock worth $253K as of Q2 2026.
  • IRulya Therapeutics Inc. Common Stock was a new Boothbay Fund Management position in Q2 2026.
  • IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1818 holding.
  • Boothbay Fund Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2020 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.